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degradation induced by the Akt inhibitor API-1,
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Background: The novel Akt inhibitor, API-1, induces apoptosis through undefined mechanisms. The current study
focuses on revealing the mechanisms by which API-1 induces apoptosis.
Results: API-1 rapidly and potently reduced the levels of Mcl-1 primarily in API-1-senstive lung cancer cell lines.
Ectopic expression of Mcl-1 protected cells from induction of apoptosis by API-1. API-1 treatment decreased the
half-life of Mcl-1, whereas inhibition of the proteasome with MG132 rescued Mcl-1 reduction induced by API-1.
API-1 decreased Mcl-1 levels accompanied with a rapid increase in Mcl-1 phosphorylation (S159/T163). Moreover,
inhibition of GSK3 inhibited Mcl-1 phosphorylation and reduction induced by API-1 and antagonized the effect of
API-1 on induction of apoptosis. Knockdown of either FBXW7 or β-TrCP alone, both of which are E3 ubiquitin
ligases involved in Mcl-1 degradation, only partially rescued Mcl-1 reduction induced by API-1. However, double
knockdown of both E3 ubiquitin ligases enhanced the rescue of API-1-induced Mcl-1 reduction.
Conclusions: API-1 induces GSK3-dependent, β-TrCP- and FBXW7-mediated Mcl-1 degradation, resulting in
induction of apoptosis.
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API-1 (4-amino-5,8-dihydro-5-oxo-8-β-D-ribofuranosyl-
pyrido[2,3-d]pyrimidine-6-carboxamide) is a recently iden-
tified novel Akt inhibitor. It inhibits Akt activity through
binding to the pleckstrin homology domain of Akt and
blocking its membrane translocation [1]. API-1 possesses
promising anticancer activity, evidenced by its ability to
suppress cell growth, induce apoptosis and inhibit the
growth of cancer xenografts, particularly those with acti-
vated Akt, in nude mice [1]. We have recently shown that
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reproduction in any medium, provided the orand enhances tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis in human non-
small cell lung cancer (NSCLC) cells [2]. c-FLIP degradation
clearly contributes to the enhancement of TRAIL-induced
apoptosis by API-1 [2]. However, the mechanisms by which
API-1 induces apoptosis in cancer cells and the additional
mechanisms accounting for API-1-mediated augmentation
of TRAIL-induced apoptosis are largely unknown.
In addition to the extrinsic death receptor-mediated apop-
totic pathway, which is characterized by the oligomerization
of cell surface death receptors and activation of caspase-8,
the intrinsic apoptotic pathway that involves the disruption
of mitochondrial membranes, release of cytochrome c and
activation of caspase-9 is another critical apoptotic mechan-
ism [3]. It is known that the intrinsic apoptotic pathway is
negatively regulated by anti-apoptotic Bcl-2 family mem-
bers (e.g., Mcl-1, Bcl-2 and Bcl-XL) and inhibitor of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulation of these anti-apoptotic proteins can trigger
apoptosis or augment TRAIL-induced apoptosis [4-6].
Among the anti-apoptotic Bcl-2 family members,
Mcl-1 is known to be a short-lived protein that undergoes
ubiquitination/proteasome-mediated degradation [7]. One
degradation mechanism involves glycogen synthase kinase
3 (GSK3), which phosphorylates Mcl-1 at S159, triggering
Mcl-1 degradation [8,9]. It has been suggested that Mcl-1
phosphorylation at S159 facilitates the association of
Mcl-1 with the E3 ligase β-transducin repeats-containing
protein (β-TrCP), resulting in β-TrCP-mediated ubiquiti-
nation and degradation of Mcl-1. Recently two studies
have suggested that phosphorylation at S159 enhances the
association of Mcl-1 with the E3 ligase F-box/WD repeat-
containing protein 7 (FBXW7), resulting in FBXW7-mediated
ubiquitination and degradation of Mcl-1 [10,11].
In this study, we focused on revealing mechanisms by
which API-1 induces apoptosis of cancer cells and un-
covered GSK3-dependent Mcl-1 degradation as a critical
mechanism accounting for induction of apoptosis by
API-1. This mechanism also contributes to augmenta-
tion of TRAIL-induced apoptosis by API-1.
Methods
Reagents
API-1 (NSC177233) was obtained from the National
Cancer Institute (Bethesda, MD). MK2206 was pur-
chased from Active Biochem (Maplewood, NJ). They
were dissolved in DMSO and stored at −80°C. Soluble
recombinant human TRAIL was purchased from Pepro-
Tech, Inc. (Rocky Hill, NJ). The proteasome inhibitor
MG132, the protein synthesis inhibitor cycloheximide
(CHX) and the GSK3 inhibitor SB216763 were purchased
from Sigma Chemical Co. (St. Louis, MO). The neddyla-
tion inhibitor MLN4924 was provided by Millennium
Pharmaceuticals, Inc (Cambridge, MA). Expression
plasmids in pCI vector carrying wild-type and mutant
(S159A) human Mcl-1 were provided by Dr. X. Deng
(Emory University, Atlanta, GA). Mouse monoclonal sur-
vivin and caspase-8 antibodies and rabbit polyclonal Bim,
caspase-9 and PARP antibodies were purchased from Cell
Signaling Technology (Danvers, MA). Mouse monoclonal
caspase-3 antibody was purchased from Imgenex (San
Diego, CA). Rabbit polyclonal Mcl-1, Bad, Bcl-XL and
SKP1 and mouse monoclonal Bcl-2, Cul-1 and α-tubulin
antibodies were purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA). GSK3α/β antibody was pur-
chased from Upstate/Millipore (Billerica, MA). Mouse
monoclonal Bax and rabbit polyclonal glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibodies were
purchased from Trevigen Inc. (Gaithersburg, MD). Both
polyclonal and monoclonal actin antibodies were pur-
chased from Sigma Chemical Co.Cell lines and cell culture
The human NSCLC cell lines used in this study includ-
ing those stably expressing ectopic Mcl-1 or survivin
were described previously [12-14]. A549 cells were re-
cently authenticated by Genetica DNA Laboratories, Inc.
(Cincinnati, OH) through analyzing short tandem repeat
DNA profile; other cell lines have not been authenti-
cated. HCT116/wild type (WT) and HCT116/FBXW7-
KO cell lines were kindly provided by Dr. B. Vogelstein
(Johns Hopkins University School of Medicine, Baltimore,
MA). These cell lines were grown in monolayer culture in
RPMI 1640 medium or McCoy’s medium supplemented
with glutamine and 5% fetal bovine serum at 37°C in a hu-
midified atmosphere consisting of 5% CO2 and 95% air.
Cell survival and apoptotic assays
Cells were seeded in 96-well cell culture plates and
treated the next day with the given agents. Viable cell
numbers were determined using sulforhodamine B
(SRB) assay as described previously [15]. Combination
index (CI) for drug interaction (e.g., synergy) was calcu-
lated using the CompuSyn software (ComboSyn, Inc.;
Paramus, NJ). Apoptosis was evaluated with an annexin
V-PE apoptosis detection kit (BD Biosciences; San Jose,
CA) according to the manufacturer’s instructions. We
also detected caspases and PARP cleavage by Western
blot analysis as described below as additional indicators
of apoptosis.
Western blot analysis
Preparation of whole-cell protein lysates and Western
blot analysis were described previously [16,17].
Small interfering RNA (siRNA) and transfection
GSK3α/β siRNA (#6301) was purchased from Cell
Signaling Technology. FBXW7 siRNA that targets the
sequence of 5′-AACACAAAGCTGGTGTGTGCA-3′
[18] was synthesized from Qiagen (Valencia, CA) and used
in our previous study [13]. Cullin 1 (Cul1; sc-35126),
SKP1 (sc-29482) and β-TrCP (sc-37178) siRNAs were
purchased from Santa Cruz Biotechnology, Inc. siRNA
transfection was performed with HiPerFect transfection
reagent (Qiagen) or Lipofectamine 2000 (Invitrogen) fol-
lowing the manufacturer’s instructions.
Reverse transcription-PCR (RT-PCR)
To confirm knockdown efficiencies of β-TrCP and
FBXW7 siRNA, Control, β-TrCP, FBXW7 and β-TrCP
plus FBXW7 siRNAs were transfected into H1299 cells
with Lipofectamine 2000. After 48 h, total RNA was then
prepared from the cells by Trizol (Sigma). Reverse tran-
scription was performed with iScript select cDNA syn-
thesis kit (Bio-Rad; Hercules, CA), followed with PCR
using primers as follows: β-TrCP, 5′-CCCCAACTGACAT
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AA-3′ (reverse) [19]; FBXW7, 5′-AAAGAGTTGTTAG
CGGTTCTCG-3′ (forward) and 5′-CCACATGGATAC
CATC AAACTG-3′ (reverse) [20]; GAPDH, 5′-TGAT
GACATCAAGAAGGTGGTGAAG-3′ (forward) and 5′-
TCCTTGGAGGCCATGTGGGCCAT-3′ (reverse) [21].
Using the same assay, Mcl-l mRNA expression in cells
exposed to API-1 was detected with the following primers:
5′-TAAGGACAAAACGGGACTGG-3′ (forward) and 5′-
ACCAGCTCCTACTCCAGCAA-3′ (reverse) [22].
Results
API-1 induces Mcl-1 reduction in API-1 sensitive NSCLC
cell lines
Human NSCLC cell lines exhibited varied sensitivities to
API-1 as evaluated with the SRB assay after a 3-day in-
cubation (Figure 1A). Among them, H1299, H522 and
A549 were sensitive to API-1, whereas H226 and H1792
were quite resistant to API-1. Since our previous work
investigated the effects of API-1 on the expression of
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Figure 1 API-1 decreases Mcl-1 levels (B-D) in API-1-sensitive NSCLC c
concentrations of API-1 ranging from 10 to 0.5 μM for 3 days. Cell numbers
replicate determinations. B-D, The given cell lines were treated with differe
API-1 for the indicated times (C). The cells were then harvested for prepara
to detect the indicated proteins.the extrinsic apoptotic pathway [2], we focused our
current study on determining the effects of API-1 on
modulation of the levels of several proteins (e.g., Mcl-1
and survivin) involved in regulation of the intrinsic
apoptotic pathway. In H1299 cells, API-1 decreased the
levels of Mcl-1 and survivin at even 2.5 μM and the
levels of Bcl-2 and Bcl-XL at 10 μM with no apparent in-
crease in the levels of the pro-apoptotic proteins, Bax,
Bad and Bim (Figure 1B). Moreover, we found that API-
1 decreased Mcl-1 levels at 4 h, survivin levels at 8 h
and Bcl-2 levels at 12 h post treatment (Figure 1C), indi-
cating that Mcl-1 reduction is a rapid event ahead of
survivin and Bcl-2 decrease in the process of API-1-
induced apoptosis. By further comparing effects of API-
1 on reducing Mcl-1 and survivin in 4 more NSCLC cell
lines with different sensitivities to API-1, We found that
API-1 reduced Mcl-1 levels effectively in H522 and
A549 cells, which are sensitive to API-1, but only minim-
ally in H226 and H1792 cells, which are insensitive to
API-1. We detected survivin reduction in all four cell lines
post API-1 treatment regardless of their sensitivities to0   2.5   5  10
H1299
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ell lines (A). A, The given cell lines were treated with different
were then estimated with the SRB assay. Data are means ± SDs of four
nt concentrations of API-1 as indicated for 12 h (B and D) or 5 μM
tion of whole-cell protein lysates and subsequent Western blot analysis
Ren et al. Molecular Cancer 2013, 12:146 Page 4 of 11
http://www.molecular-cancer.com/content/12/1/146API-1 (Figure 1D). These data emphasize the relevance
and importance of Mcl-1 reduction in cell response to
API-1.
Enforced expression of ectopic Mcl-1 protects NSCLC cells
from induction of apoptosis by API-1 or API-1 combined
with TRAIL
We next determined whether Mcl-1 and survivin reduc-
tion is indeed involved in mediating induction of apop-
tosis by API-1. To this end, we enforced the expression
of ectopic Mcl-1 or survivin in NSCLC cells and then
examined their protective effects on API-1-induced
apoptosis. In both H1299 and A549 cells, API-1 treat-
ment caused clear cleavage of caspase-8, caspase-9,
caspase-3 and PARP in vector control cell lines; these ef-
fects were not observed or were drastically diminished
in Mcl-1-transfected cell lines (Figure 2A). Moreover,
API-1 did not or only minimally increased annexin V-API-1:    
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Figure 2 Enforced expression of ectopic Mcl-1 (A and B), but not surv
including caspase activation. A and B, The indicated stable transfectants w
of whole-cell protein lysates and subsequent Western blot analysis to detect c
(i.e., annexin V-positive cells) with flow cytometry (B). P, parental; V, vector. C,
API-1 for 24 h and then harvested for preparation of whole cell protein lysate
transfectants were treated with different concentrations of API-1 as indicated
means ± SDs of four replicate determinations. CF, cleaved fragment.positive (i.e., apoptotic) cell populations in both H1299/
Mcl-1 and A549/Mcl-1 cell lines, but drastically in their
matched control counterparts (Figure 2B). These results
clearly indicate that enforced expression of ectopic Mcl-1
protects cells from undergoing API-1-induced apoptosis,
suggesting that Mcl-1 reduction is indeed critical for medi-
ating apoptosis induced by API-1. In contrast, enforced
expression of ectopic survivin failed to protect cells from
killing by API-1: survivin-transfected cells were even
more sensitive than the control Lac Z-expressing cells
to the effects of API-1 on PARP cleavage and cell
survival (Figure 2C-D), suggesting that survivin reduc-
tion is less important than Mcl-1 in mediating induc-
tion of apoptosis by API-1.
We also asked whether Mcl-1 reduction contributes to
enhancement of TRAIL-induced apoptosis by API-1.
We found that the combination of API-1 and TRAIL was
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s and subsequent Western blot analysis. D, The indicated H157 stable
for 3 days. Cell numbers were estimated with SRB assay. The data are
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we previously reported [2]; these effects were substan-
tially diminished in A549/Mcl-1 cells (Figure 3). Hence,
it is clear that enforced Mcl-1 expression protects cells
from undergoing apoptosis by the API-1 and TRAIL
combination, suggesting that Mcl-1 reduction also
contributes to augmentation of TRAIL-induced apop-
tosis by API-1. Collectively, these results provide a
strong justification to focus our further studies on
addressing the mechanisms by which API-1 induces
Mcl-1 reduction.
API-1 facilitates proteasomal degradation of Mcl-1
To elucidate the mechanisms by which API-1 reduces
Mcl-1 levels, we detected Mcl-1 mRNA expression in
cells exposed to different concentrations of API-1 with
RT-PCR and found that API-1 did not alter Mcl-1
mRNA levels (Figure 4A). Since Mcl-1 is known to be a
protein subject to proteasomal degradation [23,24], we
next determined whether API-1-induced Mcl-1 reduc-
tion is due to enhancement of its degradation. Hence,
we compared the effects of API-1 on Mcl-1 reduction in
the absence and presence of the proteasome inhibitor
MG132 in a few of NSCLC cell lines. API-1 effectively
decreased Mcl-1 levels in the absence of MG132, but
failed to do so in the presence of MG132 (Figure 4B),
indicating that API-1 indeed induces proteasomal deg-
radation of Mcl-1. Moreover, we found that the half-life
of Mcl-1 in API-1-treated cells (about 20 min) was
shorter than that in DMSO-treated cells (about 90 min)
(Figure 4C), indicating that API-1 decreases the stability
of Mcl-1. Taken together, we conclude that API-1 facili-
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Figure 3 Figure Enforced expression of ectopic Mcl-1 in A549 cells pr
combination. A, The indicated stable transfectants seeded in 96 well-plate
of TRAIL alone and API-1 in combination with TRAIL. After 24 h, the cell nu
four replicate determinations. B, The indicated stable transfectants were tre
for 22 h and then harvested for preparation of whole-cell protein lysates an
cleaved form.API-1 induces GSK3-dependent Mcl-1 degradation
It is known that GSK3-mediated phosphorylation of
Mcl-1 at S159 can trigger proteasomal degradation of
Mcl-1 [8-11]. We therefore detected Mcl-1 phosphoryl-
ation in cells exposed to API-1. In API-1 sensitive
H1299 and H522 cells, we detected a rapid and robust
increase of p-Mcl-1 (S159/T163) early at 30 min post
API-1 treatment followed by reduction of total levels of
Mcl-1. In contrast, we detected a weak and late increase
of p-Mcl-1 in API-1 insensitive H226 and H1792 cells
(Figure 5A). Therefore, it is clear that API-1 increases
Mcl-1 phosphorylation at S159, particularly in API-1
sensitive cell lines. We next determined whether API-1
induces a GSK3-dependent Mcl-1 reduction. The pres-
ence of the chemical GSK3 inhibitor SB216763 inhibited
Mcl-1 phosphorylation and reduction induced by API-1
in both H1299 and H522 cell lines (Figure 5B). In agree-
ment, genetic suppression of GSK3 with GSK3 siRNA
clearly rescued Mcl-1 reduction induced by API-1
(Figure 5C). Moreover, inhibition of GSK3 with SB216763
reversed the effect of API-1 on shortening the half-life
of Mcl-1 or on decreasing the stability of Mcl-1 (Figure 5D).
Together, it is apparent that API-1 induces a GSK3-
dependent Mcl-1 reduction or degradation. To further
demonstrate the requirement of GSK3-mediated S159
phosphorylation in API-1-induced Mcl-1 degradation, we
compared the effects of API-1 on reducing the levels of
ectopically expressed wild-type and mutant Mcl-1, in
which serine 159 (S159) was changed into alanine
(S159A). As presented in Figure 5E, API-1 effectively de-
creased the levels of wild-type Mcl-1, but did not alter the
levels of Mcl-1 (S159A). Hence, it is clear that the phos-
phorylation of S159 in Mcl-1 is an essential step for API-
1-induced Mcl-1 degradation.B
A549/V  A549/Mcl-1  
otects cells from apoptosis induced by the API-1 and TRAIL
s were treated with 5 μM API-1 alone, the indicated concentrations
mbers were estimated with SRB assay. The data are means ± SDs of
ated with 5 μM API-1 alone, 30 ng/ml TRAIL alone or their combination
d subsequent Western blot analysis to detect PARP cleavage. CF,
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Figure 4 API-1 induces proteasome-mediated Mcl-1 degradation (B) and decreases Mcl-1 stability (C) without altering Mcl-1 mRNA
levels (A). A, H1299 cells were exposed to the indicated concentrations of API-1 for 8 h. Total cellular RNA was then isolated from the cells for
detection of Mcl-1 and GAPDH (internal control) mRNAs with RT-PCR. B, The indicated cell lines were pre-treated with 20 μM MG132 for
30 minutes prior to the addition of 5 μM API-1. After co-treatment for an additional 4 h, the cells were harvested for preparation of
whole-cell protein lysates and subsequent Western blot analysis. C, H1299 cells were treated with 5 μM API-1 for 8 h. The cells were then washed
with PBS 3 times and refed with fresh medium containing 10 μg/ml CHX. At the indicated times, the cells were harvested for preparation of whole-cell
protein lysates and subsequent Western blot analysis. Protein levels were quantified with NIH Image J software (Bethesda, MA) and were normalized to
actin. The results were plotted as the relative Mcl-1 levels compared to those at the time 0 of CHX treatment (right panel).
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If Mcl-1 reduction is a key event that mediates induction
of apoptosis, we anticipated that blockage of GSK3-
dependent Mcl-1 reduction will impair its ability to
cause apoptosis. Hence, we further determined the im-
pact of GSK3 inhibition on the ability of API-1 to induce
apoptosis. By comparing the effects of API-1 on decreas-
ing cell survival and inducing cleavage of caspases in the
absence and presence of SB216763, we observed that co-
treatment of cells with the API-1 and SB216763 combin-
ation was much weaker than API-1 alone in decreasing
cell survival (Figure 6A) and in inducing cleavage of
caspases including caspase-8, caspase-9, caspase-3 and
PARP (Figure 6B) in both H1299 and H522 cells. The
CIs for most combinations were > 1, suggesting antag-
onistic effects (Figure 6A). Thus, these data support the
conclusion that API-1 also induces GSK3-dependent
apoptosis.
The SKP1-Cul1-F-box protein (SCF) E3 ligases, β-TrCP and
FBXW7, are involved in mediating Mcl-1 degradation
induced by API-1
Finally, we investigated which E3 ubiquitin ligase is re-
sponsible for the GSK3-dependent proteasomal deg-
radation of Mcl-1 induced by API-1. Given the recent
studies on the critical role of FBXW7 in mediating GSK3-
dependent degradation of Mcl-1 [10,11], we first deter-
mined whether this E3 ligase is involved in API-1-induced
Mcl-1 degradation. Using the validated FBXW7 siRNA inour previous study [13], we detected slightly less re-
duction of Mcl-1 in FBXW7 siRNA-transfected cells than
in control siRNA-transfected cells (Figure 7A). We further
compared the effects of API-1 on Mcl-1 reduction be-
tween WT and FBXW7-KO HCT116 cells and generated
similar results (Figure 7A) as we observed in the above
knockdown experiment. These data collectively suggest
that FBXW7 is only partly involved in mediating GSK3-
dependent degradation of Mcl-1 by API-1, and that add-
itional E3 ligases(s) are also involved in this process.
β-TrCP was previously suggested to mediate GSK3-
dependent degradation of Mcl-1 [8]. We next determined
whether this E3 ligase contributes to GSK3-dependent
Mcl-1 degradation induced by API-1. Because both
FBXW7 and β-TrCP are SCF E3 ligases and neddylation
of Cul1 is required for the activity of SCF E3 ligases [25],
we determined whether API-1 induces Mcl-1 degrad-
ation through a SCF E3 ligase-dependent mechanism.
Inhibition of neddylation with MLN4924 impaired the
ability of API-1 to decrease Mcl-1 levels (Figure 7B). In
agreement, disruption of the SCF complex by knocking
down of SKP1, Cul1 or both substantially rescued Mcl-1
reduction caused by API-1 (Figure 7C). These data clearly
indicate the involvement of SCF E3 ligases in mediating
API-1-induced Mcl-1 degradation. Following these experi-
ments, we determined whether β-TrCP is involved in
this process. As shown in Figure 7C, knockdown of
β-TrCP substantially attenuated the ability of API-1
to decrease Mcl-1 levels, as did knockdown of Cul1
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Figure 5 API-1 induces GSK3-dependent Mcl-1 phosphorylation and degradation. A, The given cell lines were treated with 5 μM API-1 for
different times as indicated. B, The given cell lines were pre-treated with 10 μM SB216763 for 30 min and then co-treated with 5 μM API-1 for an
additional 2 h. C, The indicated cell lines were transfected with control (Ctrl) or GSK3α/β siRNA and 48 h later were exposed to DMSO or 5 μM
API-1 for additional 4 h. D, H1299 cells were pre-treated with 10 μM SB216763 (SB) for 30 min and then co-treated with 5 μM API-1 for additional
4 h. The cells were then washed with PBS 3 times, refed with fresh medium containing 10 μg/ml CHX and cultured for the indicated times.
E, The indicated plasmids were transfected into 293 T cells. After 48 h, the cells were treated with 5 μM API-1 for an additional 4 h. After the
aforementioned treatments, the cells were harvested for preparation of whole-cell protein lysates and subsequent Western blotting. Protein levels
were quantified with NIH Image J software and were normalized to actin. The results were plotted as the relative Mcl-1 levels compared to those
at the time 0 of CHX treatment (D). LE, longer exposure.
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http://www.molecular-cancer.com/content/12/1/146or SKP1, indicating that β-TrCP is indeed involved in me-
diating Mcl-1 degradation induced by API-1. Compared
to the effects of β-TrCP or FBXW7 knockdown alone, co-
knockdown of both β-TrCP and FBXW7 enhanced the
rescuing effect on Mcl-1 reduction induced by API-1(Figure 7D). The knockdown efficiencies of β-TrCP
siRNA, FBXW7 siRNA or their combination were evalu-
ated with RT-PCR (Figure 7E). Collectively, we suggest
that both β-TrCP and FBXW7 are responsible for GSK3-
dependent degradation of Mcl-1 induced by API-1.
API-1:    
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Figure 6 Inhibition of GSK3 with SB216763 antagonizes the effects of API-1 on decreasing cell survival (A) and inducing caspase
cleavage (B). A, The indicated cell lines were exposed to different concentrations of API-1 alone, SB216763 alone and the combination of API-1
and SB216763. After 3 days, cell numbers were estimated with the SRB assay. Data are means ± SDs of four replicate determinations. The numbers
in the graphs are CIs for the indicated combinations. B, The given cell lines were pre-treated with 10 μM SB216763 for 30 min and then
co-treated with 5 μM API-1 for 24 h and then harvested for preparation of whole-cell protein lysates and subsequent Western blotting.
CF, cleaved form.
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Mcl-1 is a well-known Bcl-2 family protein that nega-
tively regulates apoptosis by binding and sequestering
the pro-apoptotic proteins such as Bax, Bak, Noxa, and
Bim [7]. In this study, we found that API-1 rapidly and
potently decreased Mcl-1 levels in NSCLC cell lines sen-
sitive to API-1, but only minimally in API-1-insenstive
cell lines. Moreover, enforced expression of ectopic Mcl-1
substantially protected NSCLC cells from undergoing
apoptosis induced by API-1. These results clearly demon-
strated that Mcl-1 reduction is an essential event for API-
1 to induce apoptosis. In this study, API-1 also reduced
the levels of survivin, another important anti-apoptotic
protein that acts downstream of Mcl-1 as an endogenous
inhibitor of caspases (e.g., caspase-9) [26]. However, we
failed to demonstrate its essential role in mediating induc-
tion of apoptosis by API-1 because API-1 decreased survi-
vin levels in NSCLC cells regardless of their sensitivities to
API-1 and was equally effective in killing both NSCLC
cells carrying a vector control and those expressing ec-
topic survivin. Hence the finding of Mc1 reduction as a
critical mechanism accounting for API-1-induced apop-
tosis is novel. The current study focuses on demonstrating
the role of Mcl-1 suppression in API-1-induced apoptosis.
However, this does not exclude other targets or
mechanisms such as Bcl-1 reduction described in this
study (Figure 1) and c-FLIP degradation reportedpreviously [2] that may account for API-1-induced apop-
tosis, particularly in a given cancer cell line. It is more
likely that the effect of API-1 on induction of apoptosis is
an outcome of the combination of multiple mechanisms
including Mcl-1 reduction.
We noted that enforced expression of ectopic Mcl-1
blocked cleavage of not only caspase-9, but also caspase-
8. It is very likely that caspase-8 activation caused by
API-1 is secondary to activation of the intrinsic apop-
totic pathway because caspase-8 can be activated by
caspase-9 or caspase-3 [27,28]. However, we currently
cannot rule out the possibility that caspase-8 activation
is caused by Mcl-1 suppression if Mcl-1 has an uncov-
ered role in direct suppression of the extrinsic apoptotic
pathway.
We previously reported that API-1 effectively enhances
TRAIL-induced apoptosis in human NSCLC cells involv-
ing induction of c-FLIP degradation [2]. In this study, we
found that enforced expression of ectopic Mcl-1 protected
NSCLC cells from induction of apoptosis by the combin-
ation of API-1 and TRAIL. Hence, it is apparent that Mcl-
1 reduction is also an important mechanism by which
API-1 augments TRAIL-induced apoptosis.
Mcl-1 is known to undergo GSK3-dependent protea-
somal degradation [7,23]. As an Akt inhibitor, it was
plausible to speculate that API-1 reduces Mcl-1 levels
through activating GSK3 followed by enhancing GSK3-
A
C
API-1 [ M]:     0   2.5   5    0    2.5    5    0   2.5    5
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Figure 7 Both the SCF E3 ligases, β-TrCP and FBXW7, are involved in mediating API-1-induced Mcl-1 degradation. A, H1299 cells were
transfected with control (Ctrl) or FBXW7 siRNA and 48 h later were exposed to DMSO or 5 μM API-1 for an additional 4 h. Moreover, WT and
FBXW7-KO HCT116 cell lines were treated with 5 μM for 4 h. B, H1299 cells were pre-treated with the indicated concentrations of MLN4924 and
then co-treated with the given concentrations of API-1 for an additional 4 h. C and D, H1299 cells were transfected with the given siRNAs for
48 h and then exposed to 5 μM API-1 for another 4 h. After these treatments, the cells were harvested for preparation of whole-cell protein
lysates and subsequent Western blotting. Protein levels were quantified with NIH Image J software and were normalized to actin. E, H1299 cells
were transfected with the given siRNAs and after 48 h were harvested for extraction of total RNA. RT-PCR was then conducted to detect the
expression of the indicated mRNAs.
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not alter Mcl-1 mRNA levels, suggesting that API-1-
induced Mcl-1 reduction is likely to be a posttranscrip-
tional event. Indeed, inhibition of proteasome with MG132
rescued Mcl-1 reduction induced by API-1. Moreover,
API-1 decreased Mcl-1 stability. Hence, it is clear that
API-1 induces proteasomal degradation of Mcl-1, leading
to Mcl-1 reduction. We observed that decreased Mcl-1
levels were accompanied with an early and robust increase
in Mcl-1 phosphorylation at S159/T163, primarily in in
those NSCLC cell lines sensitive to API-1. Importantly,
suppression of GSK3 inhibited Mcl-1 phosphorylation and
reduction or degradation induced by API-1. In agree-
ment, API-1 lost its activity on inducing degradation of
mutant Mcl-1 (S159A), in which S159 could not bephosphorylated. Collectively, we conclude that API-1 de-
creases Mcl-1 levels through facilitating GSK3-dependent
proteasomal degradation of Mcl-1.
In our study, we found that inhibition of GSK3
(e.g., with SB216763) antagonized the effects of API-1 on
decreasing the survival of NSCLC cells and on inducing
cleavage of caspases and PARP. Thus, it is clear that API-1
induces GSK3-dependent apoptosis as well. This rein-
forces the critical role of GSK3-dependent Mcl-1 reduc-
tion in mediating apoptosis induced by API-1. This
finding also implies that, to prevent potential antagonism,
API-1 should not be used in combination with any agents
that may inhibit GSK3 activity in the treatment of cancer.
Although FBXW7 has been recently suggested to be
a key E3 ligase that mediates GSK3-dependent Mcl-1
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knockout of FBXW7 provided only limited protective
effect against Mcl-1 reduction induced by API-1.
However, this process does require activation of SCF
E3 ligases since the inhibition of SCF complex forma-
tion by knockdown of Cul1, SKP1 or both drastically
impaired the ability of API-1 to decrease Mcl-1 levels.
Hence, FBXW7 may not be the major E3 ligase respon-
sible for API-1-induced GSK3-dependent proteasomal
degradation of Mcl-1, and additional SCF E3 ligase(s)
may be involved in mediating GSK3-dependent degrad-
ation of Mcl-1 induced by API-1. Indeed, our further stud-
ies have shown that β-TrCP, another SCF E3 ligase
involved in mediating GSK3-dependent degradation of
Mcl-1 as suggested previously [8], also contributes to API-
1-induced Mcl-1 degradation since knockdown of β-TrCP
provided a more drastic effect than FBXW7 knockdown
on rescuing Mcl-1 reduction induced by API-1. Moreover,
we found that co-knockdown of both β-TrCP and FBXW7
exhibited much more potent effects than knockdown of
either single gene in preventing Mcl-1 reduction induced
by API-1. Therefore, we believe that both β-TrCP and
FBXW7 are involved in mediating GSK3-dependent
Mcl-1 degradation induced by API-1. Our findings
clearly suggest that two E3 ubiquitin ligases can co-
operate to regulate the degradation of one protein.
Conclusions
The current study has demonstrated that API-1 decreases
Mcl-1 levels through facilitating GSK3-dependent,
β-TrCP and FBXW7-mediated protein degradation. By re-
ducing Mcl-1 levels, API-1 is able to induce apoptosis and
sensitize cancer cells to TRAIL-induced apoptosis.
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